Salma M. Eraky

Dr. Salma M. Eraky


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
SESalma M. Eraky
Salma M. Eraky
NENada F Abo El-Magd
Nada F Abo El-Magd

1 May 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SESalma M. Eraky
Salma M. Eraky
MEMohamed El-Mesery
Mohamed El-Mesery
AEAmro El-Karef
Amro El-Karef
LELaila A. Eissa
Laila A. Eissa
AEAmal M. El-Gayar
Amal M. El-Gayar

30 November 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SESalma M. Eraky
Salma M. Eraky
NRNehal M. Ramadan
Nehal M. Ramadan
NENada F. Abo El-Magd
Nada F. Abo El-Magd

1 November 2021 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
SESalma M. Eraky
Salma M. Eraky
NRNehal M. Ramadan
Nehal M. Ramadan

19 December 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
SASamar. M. Al-Tantawy
Samar. M. Al-Tantawy
SESalma M. Eraky
Salma M. Eraky
LELaila.A. Eissa
Laila.A. Eissa
One of the most common microvascular effects of diabetes mellitus (DM) that may result in end-stage renal failure is diabetic kidney disease (DKD). Current treatments carry a substantial residual risk of disease progression regardless of treatment. By modulating various molecular targets, pentacyclic triterpenoid celastrol has been found to possess curative properties in the treatment of diabetes and other inflammatory diseases. Therefore, the present study investigated whether celastrol has anti-inflammatory, antioxidant, and antifibrotic effects as a natural compound against experimental DKD. Streptozotocin (55 mg/kg) was utilized for inducing DKD in a rat model. Antioxidant enzymes and renal function tests were assessed in serum samples. In kidney homogenate, relative miRNA-192-5p and miRNA-21-5p gene expressions were measured. Furthermore, using real-time PCR to evaluate the gene expressions of nucleus erythroid 2–related factor-2 (Nrf-2), matrix metalloproteinase-2 (MMP-2), proapoptotic caspase-3, antiapoptotic Bcl-2, LC-3, and Beclin-1. Moreover, the transforming growth factor β1 (TGF-β1), LC-3, Bcl-2, caspase-3 and NADPH oxidase 4 (NOX4) renal expressions were assessed semi-quantitatively using immunohistochemistry. Seven weeks of celastrol (1.5 mg/kg/day) treatment significantly ameliorated DKD. Celastrol improves kidney functions. Moreover, celastrol treatment demonstrated potent antioxidant effect. The mechanism of apoptosis resulting from the administration of celastrol included the modulation of Bcl-2 and caspase-3 expression in the kidney. Celasterol administration leads to an increase in LC-3 and Beclin-1 renal expression that resulting in autophagy. Celastrol treatment improved renal fibrosis by decreasing TGF-β1 and MMP-2 renal expression. These antifibrotic effects could be due to their ability to inhibit miRNA-192-5p and miRNA-21-5p expression in renal tissues. Celastrol exerts a renoprotective effect by targeting miRNA-21 and miRNA-192, as well as their downstream pathways, such as autophagy, apoptosis, and fibrosis.

13 December 2025 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
NENada F Abo El-Magd
Nada F Abo El-Magd
NRNehal S. Ramadan
Nehal S. Ramadan
YHYomna F. Hassan
Yomna F. Hassan
AMAmr M. Mahmoud
Amr M. Mahmoud
MAMaha Azzam
Maha Azzam
SESalma M. Eraky
Salma M. Eraky